DO-BO

What does environmental sustainability mean for Market Access, Gerdi Strydom?

Join us on the latest episode of MAP – the Market Access Podcast – where our host Dr. Stefan Walzer, together with special guest Gerdi Strydom, Managing Director at Valid Insight, explore the integration of ESG (Environmental, Social, and Governance) into Health Technology Assessments (HTAs).

In this episode, they unpack how healthcare’s carbon footprint and environmental impact are influencing policy, payor decisions, and industry strategies. Discover how leaders are addressing these challenges, the steps being taken in regions like the Nordics and the UK, and what the future holds for low-carbon pharmaceuticals.

This episode is for anyone who wants to get a better understanding of the growing role of environmental factors in HTAs as well as how global collaboration can drive sustainability in healthcare. Stay ahead of the trends in market access, and join the conversation around sustainability’s role in healthcare. Tune in now!

Related

In this episode of the Market Access Podcast, Erica Bersin – founder of ERO Health Communications – joins Dr. Stefan Walter to discuss the changing role of patient involvement in healthcare. Drawing on her experience in both Europe and the U.S., Erica explains how single-payer systems make patient engagement easier, while the U.S. faces more […]

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education. Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock […]

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]